Losacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losacor

Property Description
Active Ingredient Losartan Potassium (INN)
Form Oral formulation (Film-coated tablet)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Antihypertensive agent (Lowering blood pressure)
Origin Synthetic compound

Losacor: Identity, Composition, and Form

Losacor is a prescription-only medicine whose identity is defined by its single, synthetic active ingredient, Losartan Potassium. This component is the therapeutic agent in the preparation. Losacor is supplied as an oral formulation, specifically a film-coated tablet, which is designed for consistent systemic action following ingestion. As a monotherapy product, Losacor contains Losartan Potassium as the sole active pharmaceutical ingredient, distinguishing it from combination formulations often used in complex antihypertensive regimens.


Pharmacological Class and General Therapeutic Purpose

Losacor is classified as an Angiotensin II Receptor Blocker (ARB), also known as an AT1 antagonist, positioning it within the larger category of antihypertensive agents. This pharmacological class is a key component of clinical strategies for managing cardiovascular disease. The general purpose of this medication is to help reduce the sustained strain on the cardiovascular system by specifically addressing the underlying issue of elevated blood pressure. The role of the ARB class in long-term blood pressure management is widely supported by clinical consensus.


The Losartan Mechanism: High-Level Principle

Losartan’s therapeutic mechanism involves a precise physiological action to interrupt a natural hormonal pathway. Losartan selectively works by blocking the Angiotensin II type 1 receptor on blood vessel walls. Preventing the powerful hormone Angiotensin II from binding to this receptor stops the signal that typically causes the tightening, or vasoconstriction, of blood vessels. This receptor antagonism results in the blood vessels relaxing and widening (vasodilation), which directly contributes to a reduction in blood pressure and smoother blood flow.

What side effects are possible with Losacor?

Possible Side Effects and Safety Information

The established safety profile of Losacor (Losartan Potassium) is formally documented by regulatory authorities, classifying adverse reactions primarily by frequency and the organ system affected. The majority of documented side effects are categorized as common or uncommon events.

Classification Examples of Officially Listed Adverse Reactions
Common Dizziness, headache, upper respiratory infection, nasal congestion, back pain, vertigo.
Uncommon Palpitations, angina pectoris, symptomatic hypotension, rash, pruritus, gastrointestinal disturbances (diarrhea, nausea, abdominal pain).

Serious adverse reactions are rare but clinically important and include angioedema (swelling of the face, lips, tongue, and/or throat) and hepatitis, as detailed in official labeling. A safety concern requiring attention is the risk of clinically significant hyperkalemia (elevated serum potassium), particularly in susceptible patients, and potential hypotension.

Population-Specific Safety Constraints: Official regulatory documents specify important restrictions. Losacor is contraindicated in pregnancy due to the risk of fetal toxicity and is also contraindicated in severe hepatic impairment. Safety documentation notes that certain effects, such as postural hypotension (dizziness upon standing), are more frequently observed at the start of treatment or during dose escalation. The co-administration of Losacor with Aliskiren is contraindicated in patients with diabetes mellitus.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented descriptions of overdose for Losartan Potassium (Losacor) and the regulator-mandated emergency actions. It is not a guide for self-treatment.


Documented Manifestations of Overdose

Overdose resulting from excessive dosage of Losacor is primarily associated with pronounced effects on the cardiovascular system. The most likely and documented clinical sign is severe hypotension (abnormally low blood pressure). Disturbances in heart rate are also possible, including tachycardia (a rapid heart rate) or, less frequently, bradycardia (a slow heart rate).

Severe over-exposure may lead to profound hypotension, which is a life-threatening scenario requiring immediate intervention.

Neonates exposed to Losartan during the second or third trimester of pregnancy must be closely observed after birth for signs of hypotension and oliguria (low urine output).


Required Emergency Actions and Management

Seek immediate medical attention for any suspected overdose or if signs of severe low blood pressure occur.

Regulatory documentation states that no specific antidote is known for Losartan Potassium. Management of overdose is therefore symptomatic and supportive. Treatment involves close clinical observation and continuous monitoring, with the aim of supporting blood pressure and correcting conditions such as hypovolemia (low blood volume).

Losartan is highly protein-bound, and official regulatory information states that the drug is unlikely to be removed by hemodialysis in the event of an overdose.

Therapeutic Uses of Losacor

Losacor is a medication utilized in the management of specific cardiovascular and renal conditions, often as part of a patient's overall treatment plan. Its primary indications include helping to regulate high blood pressure (hypertension), which assists in mitigating associated cardiovascular risks over time. Losacor is also prescribed to support patients managing heart failure, where it may help relieve the stress on the heart muscle. Additionally, it is used to slow the progression of kidney issues in certain patients diagnosed with type 2 diabetes and concurrent hypertension. The prescribing healthcare professional determines the appropriate use of Losacor based on the patient's full medical profile and clinical scenario.


Quick Facts

Quick Fact: Support for Blood Pressure Losacor is used to help maintain appropriate blood pressure levels.

Quick Fact: Use in Heart Management Losacor provides supportive care for individuals with heart failure.

Quick Fact: Renal Support Losacor is indicated for helping to address kidney function changes in certain diabetic patients.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Losacor — official regulatory information

Eligibility scope

Scope Regulatory Statement (Losartan Potassium)
Populations for whom use is allowed (as stated in label): Adults for all indications; Children and adolescents ge 6 years for hypertension.
Populations for whom use is contraindicated: Patients with known hypersensitivity; Pregnant women (2^nd and 3^rd trimesters); Diabetic patients concomitantly using Aliskiren.
Age-related eligibility rules: Use is not recommended in children younger than 6 years or in pediatric patients with a GFR < 30 mL/min/1.73 m^2.
Condition-specific eligibility rules: Severe Hepatic Impairment is a contraindication. Mild-to-moderate Hepatic Impairment requires a lower starting dose.
Pregnancy and lactation eligibility status: Pregnancy: Contraindicated, must be discontinued immediately when detected. Lactation: Use is not recommended.
Eligibility-related restrictions: Patients with volume depletion and those with hepatic impairment are identified as groups for whom a lower starting dose is required.

Eligibility classifications (high-level)

Classification Regulatory Statement
Eligibility severity classification (as defined in official documents): Contraindicated (e.g., Pregnancy, Hypersensitivity); Not Recommended (e.g., Children < 6 years, Nursing Mothers).
Eligibility-context constraints (as defined in official documents): Use is constrained by organ function (hepatic status) and co-therapy (Aliskiren co-administration).

Resulting eligibility structure

Official eligibility statements:

  • Losacor is contraindicated and must be discontinued in pregnancy, especially during later trimesters.
  • Absolute exclusion applies to patients with hypersensitivity or diabetic patients taking Aliskiren.
  • Limited use applies to patients with hepatic impairment, who require a mandated lower initial dose.

Connection to the overall eligibility profile: Regulatory documents define Losacor eligibility through a clear structure of absolute exclusions and specific restrictions related to physiological status, age, and organ function. This approach ensures the medicine is confined to populations where its profile is established, strictly adhering to labeled contraindications and restricted-use conditions.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The officially documented interaction profile for Losacor (Losartan Potassium) focuses on modifications to systemic drug exposure and additive physiological effects. All interaction statements are derived strictly from official government regulatory documents.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Aliskiren is contraindicated in patients with Type 2 diabetes mellitus or documented renal impairment (GFR < 60 mL/min/1.73 m2). Dual blockade of the Renin-Angiotensin System (RAS) with ACE-Inhibitors is generally not recommended.

The additive pharmacological effect of Losacor with Potassium-Sparing Diuretics (e.g., Spironolactone) or Potassium Supplements increases the documented risk of hyperkalemia (elevated serum potassium levels). Furthermore, co-administration with Lithium leads to reduced renal clearance of Lithium, resulting in reversible increases in serum concentrations and toxicity.

Pharmacokinetic and Exposure Modification

Losacor is subject to documented pharmacokinetic interactions via the CYP2C9 metabolic pathway. The inhibitor Fluconazole reduces the systemic exposure of Losacor’s active metabolite while significantly increasing the exposure of Losartan itself. Conversely, the inducer Rifampicin is documented to reduce the active metabolite’s systemic exposure. Co-administration with NSAIDs may cause attenuation of the antihypertensive effect and increased risk of renal function deterioration, a risk highlighted for the elderly or volume-depleted individuals.

Mechanism of Action

Losacor (Losartan Potassium) initiates its pharmacodynamic action by acting as a specific Angiotensin II Receptor Blocker (ARB), which modulates systems that regulate vascular tone and fluid balance. The core mechanism involves the drug and its active metabolite, E-3174, engaging in antagonism of the Angiotensin II Type 1 ( AT1) receptor located on vascular smooth muscle and other tissues. By blocking the binding of Angiotensin II, this mechanism suppresses the signal for muscle contraction, leading to systemic vasodilation and a reduction in peripheral resistance. A secondary effect of AT1 receptor blockade occurs in the adrenal glands, where the normal Angiotensin II-driven stimulus for Aldosterone release is diminished. This inhibition reduces the stimulus for Aldosterone, which leads to increased renal excretion of sodium and water, modifying the overall circulating blood volume. Losartan also possesses a unique, non-RAAS related secondary mechanism by acting as an inhibitor of the Urate Transporter 1 ( URAT1) in the kidney. This action modifies the renal transport dynamics, preventing the reabsorption of uric acid and resulting in increased uricosuria (uric acid excretion).

Dosage and Administration Information

How Losacor is Used: Administration Guidelines

Losacor is approved for oral administration as either a film-coated tablet or a specially prepared oral suspension. The medication is administered once daily and may be taken with or without food. To ensure procedural consistency, the dose should be taken at approximately the same time each day.

The standard initial adult dose for hypertension and diabetic nephropathy is 50 mg once daily. Based on the individual's therapeutic response, the dose may be adjusted up to a maximum of 100 mg once daily. A lower starting dose of 25 mg once daily is recommended for patients with mild to moderate hepatic impairment or those with documented intravascular volume depletion.

For pediatric patients (aged 6 years and older with hypertension), dosing is based on body weight, starting at 0.7 mg/kg once daily, not to exceed 50 mg total. The dose may be adjusted up to a maximum of 1.4 mg/kg or 100 mg daily. The dosage is maintained long-term, and the maximal effect is typically observed within 3 to 6 weeks of starting therapy.

If a dose is missed, the guidance is to take it as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. If the oral suspension form is used, it must be accurately measured with an oral dosing device, and the prepared suspension requires refrigerated storage for up to four weeks.

Recent Clinical Evidence

Evidence for Use in High Blood Pressure (Hypertension)

The evidence base includes large-scale Randomized Controlled Trials (RCTs) where Losacor was evaluated in the context of high blood pressure. These studies monitored changes in Systolic and Diastolic Blood Pressure (BP). Long-term trials tracked the frequency of cardiovascular events such as stroke and heart attack. Studies reported measurements of lower blood pressure readings in the observed populations compared to control groups. Research exploring long-term outcomes in pediatric populations (children 6 years and older) is ongoing.

Evidence for Preventing Stroke and Kidney Protection

Losacor was evaluated in research where the study populations included patients diagnosed with hypertension and Left Ventricular Hypertrophy (LVH), monitoring the incidence of fatal and nonfatal stroke. The observed patterns for stroke outcomes differed in a specific subgroup of Black patients in one core trial.

Losacor was also studied for renal health outcomes in large-scale, placebo-controlled trials enrolling patients with Type 2 Diabetes and concurrent high blood pressure. These studies monitored severe renal events, such as the need for dialysis, and changes in proteinuria levels over time.

Evidence for Use in Heart Failure and Research Gaps

Losacor was evaluated in RCTs that included patients with symptomatic heart failure. Findings describe patterns observed in the studies regarding the occurrence of hospitalizations and cardiovascular events, supporting its role as a therapeutic option, often for patients unable to tolerate other treatments.

Research highlights what is still uncertain: data for non-diabetic kidney disease are insufficient. Comparative evidence is lacking for Losacor’s use in heart failure with preserved ejection fraction (HFpEF). The differing stroke outcomes observed in certain subgroups emphasize that study results reflect specific conditions and populations under which they were conducted.

Key Studies & References

  1. Losartan, Captopril, and Aspirin for the Prevention of Stroke and Vascular Events in Patients With Ischemic Stroke

Frequently Asked Questions (FAQ)

Common questions about Losacor (FAQ)

Q: Is Losacor the same kind of medicine as a beta-blocker?

Losacor (Losartan) is officially classified as an Angiotensin II Receptor Blocker (ARB). According to the official drug classifications, this is a different pharmacological class of medication than beta-blockers. While both ARBs and beta-blockers are used to manage high blood pressure, they interrupt different hormonal systems in the body.

Q: How quickly can I expect Losacor to start working?

Regulatory data indicates that the initial blood pressure-lowering action of Losacor may begin within approximately six hours after administration. However, the maximal or full effect of the medicine is generally reached after three to six weeks of consistent daily use.

Q: Why do some people need to take Losacor for a long time?

Losacor is indicated for the long-term management of chronic health conditions such as high blood pressure and diabetic kidney disease. These conditions often require continuous control to help reduce the risk of serious long-term cardiovascular events, such as stroke and heart attack. Official regulatory documents reflect its use as a continuous therapy.

Q: Is it common to feel tired when first starting Losacor?

Yes, official regulatory documents list fatigue (unusual tiredness or weakness) as a common adverse reaction. This means it is a side effect that has been documented in 1% to 10% of patients during clinical trials. More details are available in the official prescribing information.

Q: Can Losacor affect my ability to drive or operate machinery?

Official precautions advise that Losacor may cause side effects like dizziness or lightheadedness. These effects may be more pronounced when first starting the medicine or when the dose is increased. Official precautions emphasize that awareness of the medicine's effects is important before engaging in activities like driving or operating machinery.

Q: Is Losacor safe for use in older adults (seniors)?

The official product information does not identify specific contraindications that limit the use of Losacor in the elderly. However, regulatory data indicates that older patients may demonstrate increased sensitivity to the effects of the medicine. Regular monitoring is standard practice for this group.

Q: Can Losacor cause kidney problems over time?

Losacor works by affecting the system that regulates fluid balance. In patients who are susceptible, such as those with pre-existing heart or kidney conditions, it may cause a deterioration of renal function. Regulatory documents state that monitoring of kidney function may be necessary in these patient groups.

Q: Is Losacor known to cause weight gain?

Official adverse reaction documents do not list general weight gain as a common or uncommon side effect. However, swelling or edema is listed as a common adverse reaction. Any concerns about changes in body weight or fluid retention should be reviewed against the full safety profile.

Q: Is Losacor the generic or brand name for this medication?

Losartan Potassium is the international nonproprietary name (INN) and the generic name for the active ingredient. Losacor is a regional brand name for the product.

Q: Is it okay to take Losacor with my daily vitamin supplements?

Regulatory documents do not list specific interactions with general daily multivitamins. However, it is explicitly advised that patients should avoid potassium supplements or salt substitutes that contain potassium while taking Losacor, as the medicine can potentially increase potassium levels.

Q: Is Losacor safe to use if I have asthma or breathing difficulties?

Losacor's official safety documentation does not list asthma as a specific contraindication. However, common respiratory adverse reactions like cough or upper respiratory infection are officially documented. It is important to review the full safety profile against any existing respiratory conditions.

Q: Does Losacor cause muscle cramps or joint pain?

Yes, muscle cramps and back pain are officially documented as common adverse reactions that may occur with Losacor use. Joint pain (arthralgia) has also been reported in clinical experience.

Q: How long does the effect of Losacor last in the body?

The active substance in Losacor has an elimination half-life that supports once-daily dosing. This indicates that the medicine is designed to maintain its blood pressure-lowering effect for approximately 24 hours between administrations.

Q: Is there a risk of Losacor interacting with herbal supplements?

The official drug interaction section lists known interactions with specific prescription and over-the-counter medications. Official guidance states that patients should inform their healthcare provider about all medications and supplements, including herbal products, to help determine any potential for interaction.

Q: Are there any known interactions between Losacor and alcohol?

Official information indicates that alcohol may have an additive effect when combined with Losacor in lowering blood pressure. This combination may increase the occurrence of side effects, such as dizziness or lightheadedness.

Q: How long after starting Losacor do patients usually have check-ups?

The prescribing information emphasizes that follow-up at regular intervals is necessary to assess patient progress. This allows the prescribing doctor to check whether the medicine is working as intended and to monitor for potential unwanted effects.

Q: Is Losacor a blood thinner?

No, Losacor is not classified as a blood thinner. It is an Angiotensin II Receptor Blocker (ARB), which is used to lower blood pressure. Medicines that reduce blood clotting are known as anticoagulants or antiplatelets, which is a separate pharmacological class.

Q: Does Losacor have any known effect on sleep patterns?

Yes, official regulatory documents list insomnia (difficulty sleeping) as a common adverse reaction associated with Losacor. Additionally, general sleep disorder is listed as an uncommon adverse reaction.

Q: Does Losacor have a 'Black Box Warning' in official documents?

Yes, the Losartan product information contains an FDA Boxed Warning, which is the strongest safety warning issued by the agency. This warning is specifically related to the use of the medicine during pregnancy due to the risk of fetal toxicity.

Q: Are Losacor side effects usually temporary?

Official safety precautions note that certain effects, such as postural hypotension (dizziness upon standing), are more frequently observed at the start of treatment or when the dose is being adjusted. This suggests that some side effects may be transient.

Q: Does Losacor interact with birth control pills?

The official drug interaction list does not include a direct interaction with oral contraceptive pills. However, due to the serious risks associated with Losacor during pregnancy, regulatory documents note the importance of preventing pregnancy while using this medication.

Q: Is Losacor known to interact with common cold or flu medications?

Yes, Losacor is known to interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common ingredients in cold and flu remedies. This combination may reduce Losacor’s blood pressure-lowering effect and increase the potential risk of kidney function impairment.

Q: Why is Losacor not recommended for people with a certain kind of kidney artery issue?

Losacor works by acting on the renin-angiotensin system, which plays a vital role in regulating blood pressure to the kidneys. In patients with specific conditions, such as severe heart failure, that rely on this system, taking Losacor may lead to a deterioration of their kidney function.

Q: Do studies show Losacor causes hair loss?

Alopecia (hair loss) has been reported in postmarketing experience. Postmarketing reports are generated after the medicine is approved and do not provide reliable data on the frequency or a definitive link to the medicine.

Q: Is Losacor commonly prescribed along with other blood pressure medicines?

Yes, clinical studies and official labeling indicate that Losacor is frequently used as part of a combination therapy. It is documented to be used alongside other blood pressure-lowering agents, such as diuretics.

Q: Does Losacor affect my sense of taste?

Dysgeusia (a change or loss of the sense of taste) has been reported in the postmarketing experience for Losartan. As with other postmarketing reports, this does not provide information on the frequency or confirm the cause-and-effect relationship with the medication.

Q: Are there official guidelines about Losacor and sun exposure?

Official documentation lists photosensitivity as a dermatologic adverse reaction. Photosensitivity is an increased sensitivity of the skin to sunlight, which may lead to severe sunburn. Official documentation implies that protective measures against sun exposure may be considered.

Q: Is Losacor a preventative medicine or a treatment?

According to its official indications, Losacor is used for both the treatment of existing high blood pressure and for the risk reduction (prevention) of certain cardiovascular events like stroke in specific patient populations.

Q: Is Losacor known to cause mood changes or depression?

Depression, anxiety, and other mood-related events have been officially reported in the postmarketing experience for Losartan. These reports are generated after the drug is approved and do not provide data on the frequency or confirm the cause-and-effect relationship with the medication.

How should Losacor be stored and disposed of?

Losacor (losartan potassium tablets) must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C.

The tablets must be kept in the original container and maintained tightly closed to provide protection from excess heat, light, and moisture. Losacor should be stored out of the sight and reach of children to comply with child-safety mandates.

For the prepared oral suspension, if used, the product requires refrigeration at 2 C to 8 C (36 F to 46 F) and must be discarded after four weeks. Any unused or expired Losacor must be disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Losacor found in:

A-Z Index: